Browse through all publications from the Institute of Global Health Innovation, which our Patient Safety Research Collaboration is part of. This feed includes reports and research papers from our Centre. 

Citation

BibTex format

@article{Olupot-Olupot:2026:10.12688/wellcomeopenres.24096.2,
author = {Olupot-Olupot, P and Amorut, D and Ongodia, P and Okalebo, CB and Abeso, J and Aloroker, F and Asio, S and Odiit, A and Kiyaga, C and Muhindo, R and Uyoga, S and Mochamah, G and Muyinda, A and Abongo, G and Nyutu, G and Mogaka, C and Maitland, K and Gibb, D and Walker, AS and Connon, R and George, E and Ware, RE and Williams, TN},
doi = {10.12688/wellcomeopenres.24096.2},
journal = {Wellcome Open Research},
pages = {244--244},
title = {Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda},
url = {http://dx.doi.org/10.12688/wellcomeopenres.24096.2},
volume = {10},
year = {2026}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <ns5:p>Background Sickle cell disease is the most common and severe genetic disease in humans worldwide. The majority of those affected are born in sub-Saharan Africa, where resources to diagnose and manage them are often limited. Fresh approaches to the pragmatic management of children with sickle cell disease in Africa that improve both morbidity and mortality are urgently needed. Methods Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME) is a 2 × 2 × 2 factorial randomized open-label trial that is investigating three separate interventions. Eighteen hundred children aged 1–10 years attending sickle cell clinics at one of four sites in Eastern Uganda are being randomized to: (1) hydroxyurea administered at a low dose (10 mg/kg/day) versus high dose (25 mg/kg/day), prescribed pragmatically through a weight-band-based approach and with clinically, rather than laboratory-guided monitoring; (2) enhanced malaria prophylaxis with weekly doses of dihydroartemisinin-piperaquine versus monthly doses of sulfadoxine-pyrimethamine (standard of care); and (3) enhanced antibacterial prophylaxis with daily cotrimoxazole throughout life versus twice daily penicillin until the age of 5 years (standard of care). All children will be followed up for 48 months after the date on which the first child was randomized. The primary endpoint for the hydroxyurea randomization will be mortality, for the antimalarial randomization will be malaria-associated hospital admission, and for the antimicrobial randomization will be all-cause hospital admission. Secondary outcomes will include the incidence of sickle-specific complications, receipt of blood transfusions, hemoglobin and fetal hemoglobin concentrations, and economic costs and benefits of the three interventions. Conclusions The first participant was recruited for the trial on January 16, 2024. In total, 1487 of the 1800 target children were re
AU  - Olupot-Olupot,P
AU  - Amorut,D
AU  - Ongodia,P
AU  - Okalebo,CB
AU  - Abeso,J
AU  - Aloroker,F
AU  - Asio,S
AU  - Odiit,A
AU  - Kiyaga,C
AU  - Muhindo,R
AU  - Uyoga,S
AU  - Mochamah,G
AU  - Muyinda,A
AU  - Abongo,G
AU  - Nyutu,G
AU  - Mogaka,C
AU  - Maitland,K
AU  - Gibb,D
AU  - Walker,AS
AU  - Connon,R
AU  - George,E
AU  - Ware,RE
AU  - Williams,TN
DO  - 10.12688/wellcomeopenres.24096.2
EP  - 244
PY  - 2026///
SP  - 244
TI  - Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda
T2  - Wellcome Open Research
UR  - http://dx.doi.org/10.12688/wellcomeopenres.24096.2
UR  - https://doi.org/10.12688/wellcomeopenres.24096.2
VL  - 10
ER  -
Download